ArticleCancer2020

Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).

Hongjing Zang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.